Press coverage about Clovis Oncology (NASDAQ:CLVS) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Clovis Oncology earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.5775433602624 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Clovis Oncology (NASDAQ:CLVS) opened at 67.17 on Friday. Clovis Oncology has a 12 month low of $25.50 and a 12 month high of $99.45. The firm has a 50 day moving average of $76.78 and a 200-day moving average of $68.43. The firm’s market cap is $3.28 billion.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.27) by $0.02. The firm had revenue of $14.62 million for the quarter, compared to analyst estimates of $13.07 million. The firm’s quarterly revenue was down 32.5% on a year-over-year basis. During the same quarter last year, the firm posted ($2.07) earnings per share. On average, equities research analysts forecast that Clovis Oncology will post ($7.53) earnings per share for the current year.

A number of equities analysts recently commented on the stock. Cann reissued a “hold” rating on shares of Clovis Oncology in a research note on Monday, July 31st. Oppenheimer Holdings, Inc. assumed coverage on shares of Clovis Oncology in a report on Friday, June 23rd. They issued a “market perform” rating on the stock. Zacks Investment Research lowered shares of Clovis Oncology from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. SunTrust Banks, Inc. reaffirmed a “buy” rating on shares of Clovis Oncology in a report on Thursday, June 22nd. Finally, Gabelli assumed coverage on shares of Clovis Oncology in a report on Friday, July 7th. They issued a “buy” rating and a $125.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $85.16.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at

In related news, Director James C. Blair sold 18,450 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the sale, the director now owns 2,185 shares of the company’s stock, valued at $171,762.85. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $61.82, for a total transaction of $185,460.00. Following the sale, the insider now directly owns 200,583 shares in the company, valued at approximately $12,400,041.06. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,450 shares of company stock worth $2,120,645. Insiders own 17.40% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.